InvestorsHub Logo
Followers 276
Posts 32697
Boards Moderated 0
Alias Born 11/14/2013

Re: exwannabe post# 682401

Sunday, 03/31/2024 2:49:27 PM

Sunday, March 31, 2024 2:49:27 PM

Post# of 699722
SRD is 10.9% at risk at five years. For DCVax-l
MRD is 10.6% at risk at five years for DCVax-l

Long term survival is where the impact is expected to be highest with cancer vaccine therapy.

You’ll also notice it appears significant residual disease (where I logically assume most mesenchymal are) will surpass minimum residual disease by year six.

This would not be the case with SOC therapy. It would be the opposite, and by a much wider margin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News